Thermo Fisher Scientific Inc. (TMO) Stock

NYSE
HealthcareDiagnostics & Research Website

TMO has an Alpha Score of 44 out of 100 (weak), computed on Nov 13, 2026 from 3 of 4 sub-scores. 41 members of Congress disclosed 111 trades in TMO since 2014: 59 purchases and 52 sales, most recently Dan Newhouse (sale, Jul 10, 2026). 8 of the hedge funds AlphaScala tracks reported TMO in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Lone Pine Capital's at $672.81M. Company insiders reported 0 open-market buys and 9 sales on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 36.4 and its net margin 14.9% (key statistics as of Nov 8, 2026).

$669.54
-2.79%
Last price
Source: Finnhub
Alpha Score
44
Weak

What is TMO's Alpha Score?

How it works →

Alpha Score of 44 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
72
Moderate
Value
18
Poor
Quality
54
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 13, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Thermo Fisher Scientific Inc. (TMO)?

Members
41
Disclosed trades
111
Purchases
59
Sales
52

Most recent: Dan Newhouse (sale, Jul 10, 2026); records start Aug 19, 2014.

PoliticianTrade dateTypeAmount
Dan Newhouse
R-WA · House
2026-07-10sale$1k – $15k
Dwight Evans
D-PA · House
2026-05-07partial sale$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-27purchase$1k – $15k
Lisa McClain
R-MI · House
2025-10-31sale$1k – $15k
Lisa McClain
R-MI · House
2025-10-30purchase$1k – $15k
Lisa McClain
R-MI · House
2025-10-30sale$1k – $15k
Val Hoyle
D-OR · House
2025-09-23sale$1k – $15k
Kelly Morrison
D-MN · House
2025-08-19partial sale$15k – $50k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded TMO, with filing lags →

Which hedge funds own TMO?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Lone Pine Capital
Steve Mandel
997K$672.81MNEW
Viking Global Investors
Andreas Halvorsen
920K$620.79M-53%
Point72
Steve Cohen
366K$247.07M+32%
Maverick Capital
Lee Ainslie
298K$200.87MNEW
D.E. Shaw
David Shaw
173K$116.50M-73%
Bridgewater Associates
Ray Dalio
155K$104.39M+1094%
Citadel
Ken Griffin
150K$101.05M-74%
Millennium Management
Israel Englander
135K$91.00M-19%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Thermo Fisher Scientific Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
9
Net $
-$7.6M
Unique insiders
3
DateInsiderRoleTypeSharesValue
Nov 13, 26Pettiti GianlucaPresident & COOSELL400$281K
Nov 13, 26Pettiti GianlucaPresident & COOSELL3.7K$2.6M
Oct 28, 26Britt Lisa P.Sr. VP and Chief HR OfficerSELL2.8K$2.0M
Aug 31, 26Pettiti GianlucaPresident & COOSELL400$246K
Aug 31, 26Pettiti GianlucaPresident & COOSELL3.7K$2.3M
Aug 24, 26Casper Marc NChairman & CEOSELL101$63K
Aug 24, 26Casper Marc NChairman & CEOSELL33$21K
Aug 24, 26Casper Marc NChairman & CEOSELL79$50K
Aug 24, 26Casper Marc NChairman & CEOSELL62$39K
Aug 21, 26Casper Marc NChairman & CEOSELL2.7K$1.7M

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are TMO's key statistics?

P/E Ratio
36.41
EPS (TTM)
18.94
Dividend Yield
0.29%
Beta
0.84
Net Margin
14.93%
ROE
13.29%
Debt / Equity
0.74
52W High
$712.17
52W Low
$435.27

Key statistics as of Nov 8, 2026

How does TMO's valuation compare with the Healthcare sector?

MetricTMOHealthcare medianCompanies in median
P/E ratio36.429.1147
Net margin14.93%3.59%223
Return on equity13.29%3.41%255
Dividend yield (payers)0.29%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

What did Thermo Fisher Scientific Inc.'s latest SEC filings say?

Latest 3
8-KMar 24, 2026SEC.gov →

Thermo Fisher Scientific Completes Acquisition of Clario Holdings Inc on March 24 2026

On March 24, 2026, Thermo Fisher Scientific Inc. filed an 8-K report to formally announce the completion of its acquisition of Clario Holdings, Inc. The filing serves as a notification of this material corporate event. The company provided a press release as an exhibit to the filing, which details the finalization of the transaction. No additional financial terms or operational integration details were disclosed within the body of the 8-K filing itself, other than the confirmation of the completed acquisition.

Material changes
  • ›Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc.
  • ›The transaction was officially finalized on March 24, 2026.
  • ›The company issued a press release to confirm the closing of the deal.
10-KFeb 26, 2026SEC.gov →

Thermo Fisher Scientific Files 2025 Annual Report Detailing Financial Position and Debt

Thermo Fisher Scientific Inc. filed its 10-K for the fiscal year ended December 31, 2025. The filing provides a comprehensive overview of the company's financial structure, including its extensive portfolio of senior notes with varying maturity dates ranging from 2025 through 2049. The report outlines the company's operational segments, which include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company maintains a diverse capital structure, utilizing both fixed and floating-rate debt instruments to manage its long-term obligations. The filing includes detailed disclosures regarding property, plant, and equipment, as well as intangible assets such as customer relationships, developed technology, and trade names. The company continues to report revenue streams categorized by product and service offerings. The report also details the company's equity structure, including common stock, additional paid-in capital, and treasury stock, reflecting changes over the three-year period ending in 2025. Management continues to monitor restructuring costs and other non-operating income and expenses as part of its ongoing financial oversight.

Material changes
  • ›Detailed extensive schedule of senior notes with maturities extending to 2049.
  • ›Maintained consistent reporting across four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
  • ›Updated disclosures for property, plant, and equipment depreciation and amortization policies.
  • ›Reported ongoing management of restructuring and other non-operating costs.
  • ›Confirmed continued use of both product and service revenue classifications.
8-KFeb 12, 2026SEC.gov →

Thermo Fisher Scientific Issues $3.8 Billion in Senior Notes for Clario Acquisition

On February 12, 2026, Thermo Fisher Scientific Inc. completed a public offering of senior notes totaling $3.8 billion in aggregate principal amount. The offering consisted of four tranches: $1 billion of 4.215% notes due 2031, $750 million of 4.550% notes due 2033, $1.3 billion of 4.902% notes due 2036, and $750 million of 5.546% notes due 2046. The notes are general unsecured obligations of the company and rank equally with existing unsecured and unsubordinated indebtedness. The company expects net proceeds from the offering to be approximately $3.76 billion after accounting for underwriting discounts and estimated expenses. Thermo Fisher intends to use these proceeds primarily to fund a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc. Pending the completion of the acquisition, which remains subject to customary closing conditions and regulatory approvals, the company may use the funds for general corporate purposes, including debt repayment, working capital, capital expenditures, or share repurchases. The indenture governing the notes includes standard covenants that restrict the company and its subsidiaries from incurring debt secured by liens on principal properties or engaging in certain sale and lease-back transactions. Additionally, the company is subject to change-of-control provisions that may require a repurchase offer at 101% of the principal amount if the notes are downgraded below investment grade by at least two of the three major rating agencies following a change of control.

Material changes
  • ›Issued $3.8 billion in senior notes across four tranches maturing between 2031 and 2046.
  • ›Net proceeds of approximately $3.76 billion earmarked for the acquisition of Clario Holdings, Inc.
  • ›Notes include change-of-control provisions requiring repurchase at 101% if accompanied by an investment-grade downgrade.
  • ›Negative covenants restrict the company from placing liens on principal properties or engaging in certain sale and lease-back transactions.

TMO price chart

Powered by TradingView

What does Thermo Fisher Scientific Inc. do?

Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. The company serves pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, government agencies, and sectors including environmental, industrial, research and development, quality, and process control. Its Life Sciences Solutions segment delivers reagents, instruments, and consumables for biological and medical research, drug and vaccine discovery and production, and disease diagnosis. The Analytical Instruments segment supplies tools, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and industrial applications, as well as clinical labs. Additional offerings include lab products, services through brands like Fisher Scientific and Unity Lab Services, and biopharma capabilities via Patheon and PPD. Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, supports customers across North America, Europe, and Asia-Pacific with innovative technologies and global distribution.

CEO
Mr. Marc N. Casper
Employees
125,000
Market Cap
$257.42B
Ask about TMOAI research agent